AMERICAN RADIOSURGERY

PRESS RELEASE

For Immediate Release

Contact:
Katie Clark
American Radiosurgery
Ph: (858) 451-6173
Fax: (858) 487-0662
info@americanradiosurgery.net
www.americanradiosurgery.net

American Radiosurgery Receives FDA Approval for MRI Use with Explorer4D™ Treatment Planning System

Patients can now receive CT or MRI with the highly advanced Explorer4D used in the non-invasive treatment of brain tumors

San Diego, CA, November 21, 2010 - American Radiosurgery, Inc. announced today that the company has received notification from the Food and Drug Administration approving the use of the Explorer4D treatment planning system with magnetic resonance imaging (MRI) capabilities. Previously, Explorer4D was approved only for computed tomography (CT) medical imaging.

Explorer4D is a sophisticated software package that optimizes dose planning for use with the Rotating Gamma System (RGS) Verterx360™ in the noninvasive treatment of brain tumors and brain disorders. Explorer4D's OsiriX™ medical image viewing software platform, automatic skin detection and easy monitoring of point dose distribution represent a significant departure from the traditional treatment planning software used in other radiosurgery devices.

"Obtaining FDA approval of the MRI application of Explorer4D treatment planning system validates the efficiency of this incredible software package," said Mr. John Clark, Chairman and CEO of American Radiosurgery. He added, "Explorer4D allows practitioners to optimize dose planning for use with the RGS Vertex360 and to more effectively target lesions and tumors."

American Radiosurgery, Inc., is based in San Diego, California and is a neurosurgical/radiosurgical device company providing advanced technology for the non-invasive treatment of brain tumors and other brain disease entities.

###

Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent shareholder letter. There is no assurance any new products can be cleared for sale by the FDA or successfully commercialized or any forward-looking statements will prove accurate, as actual results and future events could differ materially from those presently anticipated.